Brava Diagnostics
Boulder
About Brava Diagnostics
Brava Diagnostics develops and commercializes acute care diagnostic products based on the MBio diagnostics rapid testing platform. It is seeking seed financing to fund product development for rapid multiplex point-of-care tests for acute care settings. The core platform uses evanescent planar waveguide technology was developed by MBio. Products have been commercialized for applications outside of human health. Brava's in-vitro diagnostics applications will be for cardiac markers, a $2.3 billion worldwide market. Our first indications will be to assess chest pain and shortness of breath in the emergency department. The next assays will address sepsis, the highest cost disease state in U.S. health systems.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.0M
- Funding stage: M&A
- Last round: Series Unknown (Nov 2018)
- Website: bravadx.com
- Phone: (661) 993-4085
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/brava-diagnostics-5979 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.